Sensus Healthcare (SRTS) closed at $2.33 on November 13, 2026, down 27.8% from the previous close, on volume of 194,347 shares (30-day average 376,137).
Data as of November 13, 2026.
13-Nov-2026
Sensus Healthcare Earnings Call Signals Growth Amid Challenges
TipRanks (Sat, 14-Nov 10:50 PM ET)
TipRanks (Sat, 14-Nov 3:45 PM ET)
Sensus Healthcare GAAP EPS of -$0.09 misses by $0.03, revenue of $6M misses by $0.61M
Seeking Alpha News (Thu, 12-Nov 5:05 PM ET)
Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights
Business Wire (Thu, 12-Nov 4:05 PM ET)
Here are the major earnings after the close Thursday
Seeking Alpha News (Thu, 12-Nov 10:00 AM ET)
Sensus Healthcare Announces Sale of 1,000th SRT System, Marking Significant Commercial Milestone
Business Wire (Tue, 10-Nov 8:00 AM ET)
Business Wire (Thu, 29-Oct 4:05 PM ET)
CMS Validates Sensus SRT: Major Coding Update Enhances Reimbursement and Expands Patient Access
Market Chameleon (Tue, 4-Nov 5:35 AM ET)
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
Sensus Healthcare trades on the NASDAQ stock market under the symbol SRTS.
As of November 13, 2026, SRTS stock price declined to $2.33 with 194,347 million shares trading.
SRTS has a beta of -0.19, meaning it tends to be less sensitive to market movements. SRTS has a correlation of 0.00 to the broad based SPY ETF.
SRTS has a market cap of $38.27 million. This is considered a Sub-Micro Cap stock.
Last quarter Sensus Healthcare reported $6 million in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-619,000 and missed earnings estimates by -$.05.
In the last 3 years, SRTS traded as high as $9.33 and as low as $1.83.
The top ETF exchange traded funds that SRTS belongs to (by Net Assets): VTI, VXF, DFAS, DFSV, DFAC.
SRTS has underperformed the market in the last year with a price return of -47.9% while the SPY ETF gained +13.4%. SRTS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -26.4% and -15.8%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
SRTS support price is $3.01 and resistance is $3.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRTS shares will trade within this expected range on the day.